BioMedNewsBreaks — Astiva Health Earns 2026 Senior Choice Gold Award for Excellence in Medicare Advantage Performance and Value

Astiva Health, a rapidly growing Medicare Advantage organization serving California’s diverse senior population, has been awarded the 2026 Senior Choice Gold Award by HealthMetrix Research Inc., recognizing its superior cost-effective coverage and culturally aligned care model. With a 4-star CMS quality rating and more than 38,000 members across the state, Astiva continues to lead in delivering high-value, community-based healthcare—particularly among underserved and multilingual populations in San Diego and Santa Clara. “This recognition reflects our commitment to not only serve, but to understand and elevate the communities we care for,” said Dr. Tri T. Nguyen, co-founder and CEO.

To view the full press release, visit https://ibn.fm/k3Zht

About Astiva Health

Astiva Health is a leader in culturally responsive healthcare solutions, committed to bridging healthcare gaps for diverse and underserved populations. With a focus on delivering personalized care, Astiva empowers its members through innovative Medicare Advantage plans, strategic partnerships, and multilingual resources. Serving over 38,000 members across California, Astiva Health is redefining healthcare accessibility and equity through community integration and culturally tailored care.

NOTE TO INVESTORS: The latest news and updates relating to ASTIVA are available in the company’s newsroom at https://ibn.fm/ASTIVA

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Q3 2025 Financial Results and Host Conference Call on Nov. 17

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced it will release its third quarter…

5 hours ago

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Bioscience Publish Landmark Review Defining Sub-15 nm Nanoparticles as New Frontier in Drug Delivery

Oncotelic Therapeutics (OTCQB: OTLC), and joint venture partner Sapu Bioscience today announced the publication of…

1 day ago

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Launches HOPE Therapeutics’ One-Day TMS Protocol for Treatment-Resistant Depression in Florida

NRx Pharmaceuticals (NASDAQ: NRXP), announced that its subsidiary, HOPE Therapeutics(TM), has initiated patient care using…

2 days ago

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) CEO Discusses AI-Driven Cancer Drug Development in FintechTV Interview at NYSE

• Lantern’s AI platform “learns, reads, models, and predicts” to identify new drugs and indications •…

2 days ago

BioMedNewsBreaks — Oncotelic Therapeutics Inc. (OTLC) Venture Begins Clinical Trials of Innovative Cancer Therapy

Oncotelic Therapeutics (OTCQB: OTLC) venture Sapu Nano recently secured approval from Australia’s Human Research Ethics Committee…

5 days ago

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Highlights Key Clinical Progress and Reports Q3 2025 Financial Results 

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company advancing treatments for rare diseases with unmet medical…

5 days ago